Samarium for osteoblastic bone metastases and osteosarcoma

Bibliography

• BAGI CM: Targeting of therapeutic agents to bone to treat metastatic cancer. Adv. Drug Deliv. Rev. (2005) 57:995-1010.
   PubMed Web of Science ®Google Scholar
• Samarium-153 lexidronam for painful bone metastases. Med. Lett. Drugs Ther. (1997) 39:83-84.
   Google Scholar
• SERAFINI AN: Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q. J. Nucl. Med. (2001) 45:91-99.
   PubMedGoogle Scholar
• VAKAET LA, BOTERBERG T: Pain control by ionizing radiation of bone metastasis. Int. J. Dev. Biol. (2004) 48:599-606.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. (2001) 27:165-176.
   PubMed Web of Science ®Google Scholar
• PEREZ JE, MACHIAVELLI M, LEONE BA et al.: Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncologico Cooperativo del Sur. Am. J. Clin. Oncol. (1990) 13:294-298.
   PubMed Web of Science ®Google Scholar
• HOSKIN PJ: Radiotherapy in the management of bone pain. Clin. Orthop. Relat. Res. (1995) 312:105-119.
   Google Scholar
• COLEMAN RE: Management of bone metastases. Oncologist (2000) 5:463-470.
   PubMedGoogle Scholar
• JANJAN N: Bone metastases: approaches to management. Semin. Oncol. (2001) 28:28-34.
   PubMed Web of Science ®Google Scholar
• SAARTO T, JANES R, TENHUNEN M, KOURI M: Palliative radiotherapy in the treatment of skeletal metastases. Eur. J. Pain (2002) 6:323-330.
   Google Scholar
• JANJAN NA, PAYNE R, GILLIS T et al.: Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J. Pain Symptom Manage. (1998) 16:171-178.
   PubMed Web of Science ®Google Scholar
• PINSKI J, DORFF TB: Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur. J. Cancer (2005) 41:932-940.
   Google Scholar
• HOSKIN PJ: Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev. (2003) 29:321-327.
   PubMed Web of Science ®Google Scholar
• GARCIA JR, SIMO M, SOLER M et al.: Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases. Eur. J. Nucl. Med. Mol. Imaging (2005) 32:1243-1244.
   Google Scholar
• PAUWELS EK, STOKKEL MP: Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice. Q. J. Nucl. Med. (2001) 45:18-26.
   PubMedGoogle Scholar
• MAHAJAN A, ANDERSON PM, HUGHES D et al.: Multimodality local management of recurent osteosarcoma including radiotherapy, samarium, and chemotherapy. Pediatric Blood and Cancer (in press).
   Google Scholar
• ANDERSON P: Osteosarcoma relapse: expect the worst, but hope for the best. Pediatr. Blood Cancer (2005) Oct 3 [Epub ahead of print].
   Google Scholar
• NAIR N: Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J. Nucl. Med. (1999) 40:256-261.
   Google Scholar
• GIAMMARILE F, MOGNETTI T, RESCHE I: Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q. J. Nucl. Med. (2001) 45:78-83.
   PubMedGoogle Scholar
• LAM MG, DE KLERK JM, VAN RIJK PP: 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur. J. Nucl. Med. Mol Imaging (2004) 31(Suppl. 1):S162-S170.
   Google Scholar
• LEWINGTON VJ: Bone-seeking radionuclides for therapy. J. Nucl. Med. (2005) 46(Suppl. 1):38S-47S.
   PubMed Web of Science ®Google Scholar
• QUIRIJNEN JM, HAN SH, ZONNENBERG BA et al.: Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J. Nucl. Med. (1996) 37:1511-1515.
   PubMed Web of Science ®Google Scholar
• LIN WY, LIN CP, YEH SJ et al.: Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur. J. Nucl. Med. (1997) 24:590-595.
   Google Scholar
• FINLAY IG, MASON MD, SHELLEY M: Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. (2005) 6:392-400.
   PubMed Web of Science ®Google Scholar
• GIRALT S, BENSINGER W, GOODMAN M et al.: 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two Phase 1/2 trials. Blood (2003) 102:2684-2691.
   PubMed Web of Science ®Google Scholar
• RAJENDRAN JG, EARY JF, BENSINGER W et al.: High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J. Nucl. Med. (2002) 43:1383-1390.
   PubMed Web of Science ®Google Scholar
• ATKINS HL, MAUSNER LF, SRIVASTAVA SC et al.: Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J. Nucl. Med. (1995) 36:725-729.
   Google Scholar
• EISENHUT M, BERBERICH R, KIMMIG B, OBERHAUSEN E: Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J. Nucl. Med. (1986) 27:1255-1261.
   PubMed Web of Science ®Google Scholar
• KUTZNER J, GRIMM W, BROD KH, ROESLER A: [Yttrium-90-therapy of bone metastases]. Dtsch. Med. Wochenschr. (1982) 107:1360-1361.
   Google Scholar
• NILSSON S, LARSEN RH, FOSSA SD et al.: First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. (2005) 11:4451-4459.
   PubMed Web of Science ®Google Scholar
• LARSEN RH, SAXTORPH H, SKYDSGAARD M et al.: Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In vivo (2006) 20:325-331.
   PubMed Web of Science ®Google Scholar
• LIEPE K, RUNGE R, KOTZERKE J: Systemic radionuclide therapy in pain palliation. Am. J. Hosp. Palliat. Care (2005) 22:457-464.
   Google Scholar
• BEN-JOSEF E, PORTER AT: Radioisotopes in the treatment of bone metastases. Ann. Med. (1997) 29:31-35.
   PubMed Web of Science ®Google Scholar
• DICKIE GJ, MACFARLANE D: Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas. Radiol. (1999) 43:476-479.
   PubMedGoogle Scholar
• LIEPE K, RUNGE R, KOTZERKE J: The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J. Cancer Res. Clin. Oncol. (2005) 131:60-66.
   Google Scholar
• MCEWAN AJ: Pain palliation and nuclear medicine. Eur. J. Nucl. Med. (1993) 20:1-3.
   Google Scholar
• MCEWAN AJ: Use of radionuclides for the palliation of bone metastases. Semin. Radiat. Oncol. (2000) 10:103-114.
   PubMed Web of Science ®Google Scholar
• SERAFINI AN: Therapy of metastatic bone pain. J. Nucl. Med. (2001) 42:895-906.
   PubMed Web of Science ®Google Scholar
• GOECKELER WF, TROUTNER DE, VOLKERT WA et al.: 153Sm radiotherapeutic bone agents. Int. J. Rad. Appl. Instrum. B (1986) 13:479-482.
   PubMedGoogle Scholar
• ATKINS HL, SRIVASTAVA SC: Radiolabeled bone-seeking radiopharmaceuticals. Q. J. Nucl. Med. (1996) 40:285-289.
   Google Scholar
• RAMAMOORTHY N, SARASWATHY P, DAS MK et al.: Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy. Nucl. Med. Commun. (2002) 23:83-89.
   Google Scholar
• GOECKELER WF, EDWARDS B, VOLKERT WA et al.: Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. (1987) 28:495-504.
   PubMed Web of Science ®Google Scholar
• KETRING AR: 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int. J. Rad. Appl. Instrum. B (1987) 14:223-232.
   Google Scholar
• VOLKERT WA, GOECKELER WF, EHRHARDT GJ, KETRING AR: Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med. (1991) 32:174-185.
   PubMed Web of Science ®Google Scholar
• BAYOUTH JE, MACEY DJ, KASI LP, FOSSELLA FV: Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J. Nucl. Med. (1994) 35:63-69.
   PubMed Web of Science ®Google Scholar
• FRANZIUS C, BIELACK S, FLEGE S et al.: High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin (2001) 40:215-220.
   PubMedGoogle Scholar
• ANDERSON PM, WISEMAN GA, DISPENZIERI A et al.: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. (2002) 20:189-196.
   PubMed Web of Science ®Google Scholar
• ANDERSON PM, WISEMAN GA, ERLANDSON L et al.: Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res. (2005) 11:6895-6900.
   PubMed Web of Science ®Google Scholar
• DISPENZIERI A, WISEMAN GA, LACY MQ et al.: A Phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 19:118-125.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ V, ERLANDSON L, ARNDT CA et al.: Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplant (2005) 9:122-126.
   PubMed Web of Science ®Google Scholar
• FRANZIUS C, BIELACK S, SCIUK J et al.: High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin (1999) 38:337-340.
   PubMedGoogle Scholar
• KENNEDY GA, DURRANT S, BUTLER J et al.: Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia (2005) 19:879-880.
   Google Scholar
• BRENNER W, KAMPEN WU, KAMPEN AM, HENZE E: Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J. Nucl. Med. (2001) 42:230-236.
   PubMed Web of Science ®Google Scholar
• LAZNICEK M, LAZNICKOVA A, BUDSKY F et al.: Comparison of biological characteristics of EDTMP complexes with 99mTc, 111In and 153Sm in rats. Appl. Radiat. Isot. (1994) 45:949-953.
   Google Scholar
• DIENER KM: Bisphosphonates for controlling pain from metastatic bone disease. Am. J. Health Syst. Pharm. (1996) 53:1917-1927.
   PubMed Web of Science ®Google Scholar
• MALMUD LS, CHARKES ND: Bone scanning: principles, technique and interpretation. Clin. Orthop. Relat. Res. (1975) 107:112-122.
   Google Scholar
• COLEMAN RE: Bisphosphonates in breast cancer. Ann. Oncol. (2005) 16:687-695.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. (1996) 335:1785-1791.
   PubMed Web of Science ®Google Scholar
• EATON CL, COLEMAN RE: Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat. Rev. (2003) 29:189-198.
   Google Scholar
• COLEMAN RE: Future directions in the treatment and prevention of bone metastases. Am. J. Clin. Oncol. (2002) 25:S32-S38.
   PubMedGoogle Scholar
• TURNER JH, CLARINGBOLD PG, HETHERINGTON EL et al.: A Phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J. Clin. Oncol. (1989) 7:1926-1931.
   PubMed Web of Science ®Google Scholar
• LOUW WK, DORMEHL IC, VAN RENSBURG AJ et al.: Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl. Med. Biol. (1996) 23:935-940.
   Google Scholar
• BAYOUTH JE, MACEY DJ: Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Med. Phys. (1993) 20:1089-1096.
   Google Scholar
• GHIRON J, VOLKERT WA, GARLICH J, HOLMES RA: Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography). Int. J. Rad. Appl. Instrum. B (1991) 18:235-240.
   Google Scholar
• TURNER JH, MARTINDALE AA, SORBY P et al.: Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur. J. Nucl. Med. (1989) 15:784-795.
   PubMedGoogle Scholar
• ESSMAN SC, LEWIS MR, MILLER WH: Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. J. Nucl. Med. (2005) 46:2076-2082.
   Google Scholar
• MILNER RJ, DORMEHL I, LOUW WK, CROFT S: Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours. J. S. Afr. Vet. Assoc. (1998) 69:12-17.
   PubMed Web of Science ®Google Scholar
• LATTIMER JC, CORWIN LA JR, STAPLETON J et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J. Nucl. Med. (1990) 31:1316-1325.
   PubMed Web of Science ®Google Scholar
• LATTIMER JC, CORWIN LA JR, STAPLETON J et al.: Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J. Nucl. Med. (1990) 31:586-593.
   PubMed Web of Science ®Google Scholar
• APPLEBAUM FR, SANDMAIER B, BROWN PA: Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP. Antibody Imunoconjugates Radiopharmaceuticals (1988) 1:263-279.
   Google Scholar
• AAS M, MOE L, GAMLEM H et al.: Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP). Clin. Cancer Res. (1999) 5:3148s-3152s.
   Google Scholar
• KVINNSLAND Y, BRULAND O, MOE L, SKRETTING A: A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma. Eur. J. Nucl. Med. Mol Imaging (2002) 29:191-197.
   Google Scholar
• MOE L, BOYSEN M, AAS M et al.: Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. J. Small Anim. Pract. (1996) 37:241-246.
   PubMed Web of Science ®Google Scholar
• DORMEHL IC, LOUW WK, SCHNEEWEISS FH et al.: Uptake of ethylenediamine tetramethylene phosphonic acid in normal bone after multiple applications. A non-human primate study. Arzneimittelforschung (1998) 48:408-414.
   Google Scholar
• FARHANGHI M, HOLMES RA, VOLKERT WA et al.: Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med. (1992) 33:1451-1458.
   PubMedGoogle Scholar
• SINGH A, HOLMES RA, FARHANGI M et al.: Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J. Nucl. Med. (1989) 30:1814-1818.
   PubMed Web of Science ®Google Scholar
• VAN RENSBURG AJ, ALBERTS AS, LOUW WK: Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J. Nucl. Med. (1998) 39:2110-2115.
   Google Scholar
• LOGAN KW, VOLKERT WA, HOLMES RA: Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J. Nucl. Med. (1987) 28:505-509.
   PubMed Web of Science ®Google Scholar
• HOLMES RA: [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin. Nucl. Med. (1992) 22:41-45.
   Google Scholar
• GOECKELER WF, STONEBURNER LK, KASI LP et al.: Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl. Med. Biol. (1993) 20:657-661.
   Google Scholar
• COLLINS C, EARY JF, DONALDSON G et al.: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a Phase I/II trial. J. Nucl. Med. (1993) 34:1839-1844.
   PubMed Web of Science ®Google Scholar
• FRANZIUS C, SCHUCK A, BIELACK SS: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. (2002) 20:1953-1954.
   PubMed Web of Science ®Google Scholar
• BARTLETT ML, WEBB M, DURRANT S et al.: Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur. J. Nucl. Med. Mol. Imaging (2002) 29:1470-1477.
   PubMed Web of Science ®Google Scholar
• TURNER JH, CLARINGBOLD PG, BERGER JD et al.: 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl. Med. Commun. (1992) 13:321-329.
   PubMed Web of Science ®Google Scholar
• SANDEMAN TF, BUDD RS, MARTIN JJ: Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin. Oncol. (1992) 4:160-164.
   PubMedGoogle Scholar
• RESCHE I, CHATAL JF, PECKING A et al.: A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer (1997) 33:1583-1591.
   PubMed Web of Science ®Google Scholar
• TURNER JH, CLARINGBOLD PG: A Phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur. J. Cancer (1991) 27:1084-1086.
   PubMed Web of Science ®Google Scholar
• ALBERTS AS, SMIT BJ, LOUW WK et al.: Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother. Oncol. (1997) 43:175-179.
   Google Scholar
• SERAFINI AN, HOUSTON SJ, RESCHE I et al.: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. (1998) 16:1574-1581.
   PubMed Web of Science ®Google Scholar
• SERAFINI AN: Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer (2000) 88:2934-2939.
   PubMedGoogle Scholar
• DE KLERK JM, VAN HET SCHIP AD, ZONNENBERG BA et al.: Phase I study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J. Nucl. Med. (1996) 37:244-249.
   Google Scholar
• DAFERMOU A, COLAMUSSI P, GIGANTI M et al.: A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. J. Nucl. Med. (2001) 28:788-798.
   PubMedGoogle Scholar
• ENRIQUE O, P Z, PRMA EP et al.: Efficacy and toxicity of Sm-153 EDTMP in palliative treatment of painful bone metastases. World J. Nucl. Med. (2002) 1:21-27.
   Google Scholar
• SARTOR O, REID RH, HOSKIN PJ et al.: Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology (2004) 63:940-945.
   PubMed Web of Science ®Google Scholar
• MENDA Y, BUSHNELL DL, WILLIAMS RD et al.: Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin. Nucl. Med. (2000) 25:698-700.
   PubMed Web of Science ®Google Scholar
• WANG RF, ZHANG CL, ZHU SL, ZHU M: A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med. Princ. Pract .(2003) 12:97-101.
   Google Scholar
• MARCUS CS, SAEED S, MLIKOTIC A et al.: Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin. Nucl. Med. (2002) 27:427-430.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE, MAJOR P, LIPTON A et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. (2005) 23:4925-4935.
   PubMed Web of Science ®Google Scholar
• PALMEDO H, MANKA-WALUCH A, ALBERS P et al.: Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized Phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J. Clin. Oncol. (2003) 21:2869-2875.
   PubMed Web of Science ®Google Scholar
• TU SM, MILLIKAN RE, MENGISTU B et al.: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised Phase II trial. Lancet (2001) 357:336-341.
   PubMed Web of Science ®Google Scholar
• MACHAK GN, TKACHEV SI, SOLOVYEV YN et al.: Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin. Proc. (2003) 78:147-155.
   PubMed Web of Science ®Google Scholar
• GOEL A, DISPENZIERI A, GEYER SM et al.: Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood (2006) 107:4063-4070.
   PubMed Web of Science ®Google Scholar
• YEH HS, SWIFT RA, FERRETTI D et al.: Phase I study of bortezomib and 153Sm-lexodronam combination for refractory and relapsed myeloma. J. Clin. Oncol. (2006) 24:450S.
   Google Scholar
• MAHAJAN A, ANDERSON PM, HUGHES D et al.: Multimodality local management of recurent osteosarcoma including radiotherapy, samarium, and chemotherapy. Pediatr. Blood Cancer (in press).
   Google Scholar
• SCIUTO R, FESTA A, REA S et al.: Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J. Nucl. Med. (2002) 43:79-86.
   PubMed Web of Science ®Google Scholar
• THIERENS HM, MONSIEURS MA, BACHER K: Patient dosimetry in radionuclide therapy: the whys and the wherefores. Nucl. Med. Commun. (2005) 26:593-599.
   Google Scholar
• CRANE CH, JANJAN NA, EVANS DB et al.: Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int. J. Pancreatol. (2001) 29:9-18.
   PubMedGoogle Scholar